Regentis Biomaterials (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC(R) using its next-generation solvent-free manufacturing process, a milestone that supports the product's planned commercial launch in Europe. The company said the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance.
GelrinC(R), which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan, targeting a U.S. cartilage repair market valued at approximately $3 billion.
For more information, view the full press release at https://ibn.fm/Ths4h.
This approval is significant because it addresses a key barrier to commercial scale production. The solvent-free process not only boosts yield but also enhances safety and environmental sustainability, which are critical for regulatory compliance and market acceptance. The improved manufacturing efficiency positions Regentis to meet the anticipated demand for GelrinC in Europe and later in the U.S., where approximately 470,000 cartilage knee repair cases occur annually with no off-the-shelf treatment available. The U.S. cartilage repair market is estimated at $3 billion, representing a substantial opportunity for Regentis if it can secure FDA approval and navigate the regulatory pathway.
The European approval also strengthens Regentis's competitive position. By partnering with leading orthopedic centers like Humanitas Research Hospital, the company is building a network of clinical expertise that can drive adoption and generate real-world evidence. The surgeon training programs are designed to ensure proper technique for the 10-minute procedure, which could reduce surgery time and improve patient outcomes. If successful, GelrinC could become the standard of care for cartilage repair, offering a cell-free, off-the-shelf solution that eliminates the need for cell harvesting and culturing, which are required by competing cell-based therapies.
Looking ahead, Regentis will need to execute its commercial launch in Europe while advancing its U.S. clinical development program. The company's forward-looking statements indicate potential risks, including regulatory hurdles and market acceptance, but the European approval for the next-generation manufacturing process is a tangible step toward bringing GelrinC to patients. Investors and healthcare providers will be watching closely as the company begins to commercialize this innovative product.
